High-concentration (20 μg g-1) tacalcitol ointment in the treatment of facial psoriasis: An 8-week open-label clinical trial

British Journal of Dermatology

Volumn 162, Issue 6, 2010, Pages 1359-1364

  Choi, J W ^a   Kwon, I H ^a   Youn, J I ^a  

^a Seoul National University   (South Korea)

Author keywords

Facial psoriasis; High concentration tacalcitol

Indexed keywords

BONALFA HIGH; TACALCITOL; UNCLASSIFIED DRUG;

ADULT; AGED; APPLICATION SITE EXFOLIATION; APPLICATION SITE REACTION; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FACIAL PSORIASIS; FACIAL PSORIASIS AREA AND SEVERITY INDEX; FEMALE; HUMAN; MALE; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; SCORING SYSTEM; SKIN IRRITATION; SKIN PRURITUS; SKIN REDNESS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; DERMATOLOGIC AGENTS; DIHYDROXYCHOLECALCIFEROLS; FACIAL DERMATOSES; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PROSPECTIVE STUDIES; PSORIASIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 77952684170     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09758.x     Document Type: Article

References (25)

1. Sato H, Sugimoto I, Matsunaga T et al. Tacalcitol (1,24(OH)2D3, TV-02) inhibits phorbol ester-induced epidermal proliferation and cutaneous inflammation, and induces epidermal differentiation in mice. Arch Dermatol Res 1996 288 : 656 663.
2. Peters DC, Balfour JA. Tacalcitol. Drugs 1997 54 : 265 271.
3. van de Kerkhof PC, Berth-Jones J, Griffiths CE et al. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br J Dermatol 2002 146 : 414 422. (Pubitemid 34603813)
4. Miyachi Y, Ohkawara A, Ohkido M et al. Long-term safety and efficacy of high-concentration (20 microg/g) tacalcitol ointment in psoriasis vulgaris. Eur J Dermatol 2002 12 : 463 468.
5. Katayama I, Ohkawara A, Ohkido M et al. High-concentration (20 mug/g) tacalcitol ointment therapy on refractory psoriasis vulgaris with low response to topical corticosteroids. Eur J Dermatol 2002 12 : 553 557.
6. Woo SM, Choi JW, Yoon HS et al. Classification of facial psoriasis based on the distributions of facial lesions. J Am Acad Dermatol 2008 58 : 959 963.
7. Yoon HS, Choi JW, Youn JI. Method of assessing involved facial areas: Rule of fours. Br J Dermatol 2008 158 : 1022 1028.
8. Harrison PV, Walker GB. Facial psoriasis. Clin Exp Dermatol 1985 10 : 41 4.
9. Bernhard JD. Facial sparing in psoriasis. Int J Dermatol 1983 22 : 291 292.
10. Young Park J, Hyun Rim J, Beom Choe Y et al. Facial psoriasis: comparison of patients with and without facial involvement. J Am Acad Dermatol 2004 50 : 582 584.
11. Bernhard JD. Is facial involvement a sign of severe psoriasis? Clin Exp Dermatol 1985 10 : 500 501.
12. Canpolat F, Cemil BC, Eskioglu F et al. Is facial involvement a sign of severe psoriasis? Eur J Dermatol 2008 18 : 169 171.
13. Mills CM, Marks R. Side effects of topical glucocorticoids. Curr Probl Dermatol 1993 21 : 122 131.
14. Bigby M. Pimecrolimus and tacrolimus for the treatment of intertriginous and facial psoriasis: Are they effective? Arch Dermatol 2005 141 : 1152 1153.
15. Lebwohl M, Freeman A, Chapman MS et al. Proven efficacy of tacrolimus for facial and intertriginous psoriasis. Arch Dermatol 2005 141 : 1154.
16. Liao YH, Chiu HC, Tseng YS, Tsai TF. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: A double-blind, randomized controlled trial. Br J Dermatol 2007 157 : 1005 1012.
17. Jacobi A, Braeutigam M, Mahler V et al. Pimecrolimus 1% cream in the treatment of facial psoriasis: A 16-week open-label study. Dermatology 2008 216 : 133 136.
18. Ortonne JP, Humbert P, Nicolas JF et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol 2003 148 : 326 333.
19. Jo SJ, Yoon HS, Youn JI. Treatment of psoriasis on the face with calcitriol ointment. Korean J Dermatol 2005 43 : 1461 1467.
20. Bouillon R, Garmyn M, Verstuyf A et al. Paracrine role for calcitriol in the immune system and skin creates new therapeutic possibilities for vitamin D analogs. Eur J Endocrinol 1995 133 : 7 16.
21. Menne T, Larsen K. Psoriasis treatment with vitamin D derivatives. Semin Dermatol 1992 11 : 278 283.
22. van de Kerkhof PC, Werfel T, Haustein UF et al. Tacalcitol ointment in the treatment of psoriasis vulgaris: A multicentre, placebo-controlled, double-blind study on efficacy and safety. Br J Dermatol 1996 135 : 758 765. (Pubitemid 26375894)
23. Gerritsen MJ, Boezeman JB, van Vlijmen-Willems IM et al. The effect of tacalcitol (1,24(OH)2D3) on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: A placebo-controlled, double-blind study. Br J Dermatol 1994 131 : 57 63.
24. Nishimura M, Makino Y, Matugi H. Tacalcitol ointment for psoriasis. Acta Derm Venereol Suppl (Stockh) 1994 186 : 166 168.
25. Schlotmann K, Ortland C, Neumann NJ et al. Placebo-controlled evaluation of the irritant potential of tacalcitol (1a,24-dihydroxyvitamin D3) in healthy volunteers. Contact Dermatitis 2000 42 : 260 263.